Texas Instruments (TXN) 10-Q23 Oct 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2024	Oct. 15, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-03761
Entity Registrant Name	TEXAS INSTRUMENTS INCORPORATED
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	75-0289970
Entity Address, Address Line One	12500 TI Boulevard
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75243
City Area Code	214
Local Phone Number	479-3773
Title of 12(b) Security	Common Stock, par value $1.00
Trading Symbol	TXN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		912,216,614
Entity Central Index Key	0000097476
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue	$ 4,151	$ 4,532	$ 11,634	$ 13,442
Cost of revenue (COR)	1,677	1,717	4,854	4,854
Gross profit	2,474	2,815	6,780	8,588
Research and development (R&D)	492	471	1,468	1,403
Selling, general and administrative (SG&A)	428	452	1,348	1,387
Restructuring charges/other	0	0	(124)	0
Operating profit	1,554	1,892	4,088	5,798
Other income (expense), net (OI&E)	131	128	384	327
Interest and debt expense	131	98	378	255
Income before income taxes	1,554	1,922	4,094	5,870
Provision for income taxes	192	213	500	731
Net income	$ 1,362	$ 1,709	$ 3,594	$ 5,139
Earnings per common share (EPS):
Basic (in dollars per share)	$ 1.48	$ 1.87	$ 3.92	$ 5.63
Diluted (in dollars per share)	$ 1.47	$ 1.85	$ 3.89	$ 5.58
Average shares outstanding:
Basic (in shares)	913	908	912	908
Diluted (in shares)	920	916	919	916
Diluted EPS:
Net income	$ 1,362	$ 1,709	$ 3,594	$ 5,139
Income allocated to RSUs	(7)	(10)	(18)	(26)
Income allocated to common stock for diluted EPS	$ 1,355	$ 1,699	$ 3,576	$ 5,113

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 1,362	$ 1,709	$ 3,594	$ 5,139
Net actuarial losses of defined benefit plans:
Adjustments, net of tax effect of $5 and ($3); $2 and ($4)	(11)	6	(5)	6
Recognized within net income, net of tax effect of ($1) and ($1); ($3) and ($3)	2	3	7	9
Prior service cost (credit) of defined benefit plans:
Recognized within net income, net of tax effect of $0 and $0; $0 and $0	1	1	1	1
Derivative instruments:
Change in fair value, net of tax effect of $0 and $0; $0 and $0	0	0	1	1
Available-for-sale investments:
Unrealized gains (losses), net of tax effect of ($4) and $0; ($2) and $0	13	1	6	2
Other comprehensive income (loss), net of taxes	5	11	10	19
Total comprehensive income	$ 1,367	$ 1,720	$ 3,604	$ 5,158

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net actuarial losses of defined benefit plans adjustment, tax effect	$ 5	$ (3)	$ 2	$ (4)
Net actuarial losses of defined benefit plans recognized within net income, tax effect	(1)	(1)	(3)	(3)
Prior service cost (credit) of defined benefit plans recognized within net income, tax effect	0	0	0	0
Derivative instruments change in fair value, tax effect	0	0	0	0
Available-for-sale investments unrealized gains (losses), tax effect	$ (4)	$ 0	$ (2)	$ 0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,589	$ 2,964
Short-term investments	6,163	5,611
Accounts receivable, net of allowances of ($23) and ($16)	1,862	1,787
Raw materials	393	420
Work in process	2,081	2,109
Finished goods	1,822	1,470
Inventories	4,296	3,999
Prepaid expenses and other current assets	962	761
Total current assets	15,872	15,122
Property, plant and equipment at cost	15,464	13,268
Accumulated depreciation	(3,662)	(3,269)
Property, plant and equipment	11,802	9,999
Goodwill	4,362	4,362
Deferred tax assets	941	757
Capitalized software licenses	229	223
Overfunded retirement plans	184	173
Other long-term assets	1,931	1,712
Total assets	35,321	32,348
Current liabilities:
Current portion of long-term debt	1,049	599
Accounts payable	794	802
Accrued compensation	721	836
Income taxes payable	108	172
Accrued expenses and other liabilities	1,014	911
Total current liabilities	3,686	3,320
Long-term debt	12,844	10,624
Underfunded retirement plans	117	108
Deferred tax liabilities	54	63
Other long-term liabilities	1,352	1,336
Total liabilities	18,053	15,451
Stockholders’ equity:
Preferred stock, $25 par value. Shares authorized – 10; none issued	0	0
Common stock, $1 par value. Shares authorized – 2,400; shares issued – 1,741	1,741	1,741
Paid-in capital	3,813	3,362
Retained earnings	52,304	52,283
Treasury common stock at cost Shares: September 30, 2024 – 829; December 31, 2023 – 832	(40,395)	(40,284)
Accumulated other comprehensive income (loss), net of taxes (AOCI)	(195)	(205)
Total stockholders’ equity	17,268	16,897
Total liabilities and stockholders’ equity	$ 35,321	$ 32,348

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Allowance for doubtful accounts receivable, current	$ (23)	$ (16)
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 25	$ 25
Preferred stock, shares authorized (in shares)	10	10
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	2,400	2,400
Common stock, shares issued (in shares)	1,741	1,741
Treasury stock (in shares)	829	832

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net income	$ 3,594	$ 5,139
Adjustments to net income:
Depreciation	1,092	853
Amortization of capitalized software	53	48
Stock compensation	309	294
Gains on sales of assets	(126)	(1)
Deferred taxes	(189)	(159)
Increase (decrease) from changes in:
Accounts receivable	(75)	(81)
Inventories	(297)	(1,151)
Prepaid expenses and other current assets	(69)	38
Accounts payable and accrued expenses	38	(23)
Accrued compensation	(127)	(97)
Income taxes payable	487	(65)
Changes in funded status of retirement plans	2	49
Other	(372)	(348)
Cash flows from operating activities	4,320	4,496
Cash flows from investing activities
Capital expenditures	(3,628)	(3,923)
Proceeds from asset sales	194	3
Purchases of short-term investments	(8,807)	(10,140)
Proceeds from short-term investments	8,461	9,976
Other	(36)	33
Cash flows from investing activities	(3,816)	(4,051)
Cash flows from financing activities
Proceeds from issuance of long-term debt	2,980	3,000
Repayment of debt	(300)	(500)
Dividends paid	(3,555)	(3,376)
Stock repurchases	(392)	(228)
Proceeds from common stock transactions	430	218
Other	(42)	(43)
Cash flows from financing activities	(879)	(929)
Net change in cash and cash equivalents	(375)	(484)
Cash and cash equivalents at beginning of period	2,964	3,050
Cash and cash equivalents at end of period	2,589	2,566
Supplemental cash flow information
Investment tax credit (ITC) used to reduce income taxes payable	532	0
Total cash benefit related to the U.S. CHIPS and Science Act	$ 532	$ 0

Description of business, includ

Description of business, including segment and geographic area information	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Description of business, including segment and geographic area information	Description of business, including segment and geographic area information We design and manufacture semiconductors that we sell to electronics designers and manufacturers all over the world. We have two reportable segments, Analog and Embedded Processing, each of which represents groups of similar products that are combined on the basis of similar design and development requirements, product characteristics, manufacturing processes and distribution channels. Our segments also reflect how management allocates resources and measures results. • Analog semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. Analog semiconductors are also used to manage power in all electronic equipment by converting, distributing, storing, discharging, isolating and measuring electrical energy, whether the equipment is plugged into a wall or using a battery. Our Analog segment consists of two major product lines: Power and Signal Chain. • Embedded Processing products are the digital “brains” of many types of electronic equipment. They are designed to handle specific tasks and can be optimized for various combinations of performance, power and cost, depending on the application. We report the results of our remaining business activities in Other. Other includes operating segments that do not meet the quantitative thresholds for individually reportable segments and cannot be aggregated with other operating segments. Other includes DLP ® products, calculators and custom ASIC products. Our centralized manufacturing and support organizations, such as facilities, procurement and logistics, provide support to our operating segments, including those in Other. Costs incurred by these organizations, including depreciation, are charged to the segments on a per-unit basis. Consequently, depreciation expense is not an independently identifiable component within the segments’ results and, therefore, is not provided. Segment information For Three Months Ended For Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenue: Analog $ 3,223 $ 3,353 $ 8,987 $ 9,920 Embedded Processing 653 890 1,920 2,616 Other 275 289 727 906 Total revenue $ 4,151 $ 4,532 $ 11,634 $ 13,442 Operating profit: Analog $ 1,316 $ 1,504 $ 3,371 $ 4,541 Embedded Processing 109 258 294 813 Other (a) 129 130 423 444 Total operating profit $ 1,554 $ 1,892 $ 4,088 $ 5,798 (a) Includes restructuring charges/other Geographic area information Our estimate for revenue based on the geographic location of our end customers’ headquarters, which represents where critical decisions are made, is as follows: For Three Months Ended For Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenue: United States $ 1,639 39 % $ 1,541 34 % $ 4,335 37 % $ 4,391 33 % China 823 20 813 18 2,191 19 2,561 19 Rest of Asia 431 10 434 10 1,249 11 1,263 10 Europe, Middle East and Africa (a) 880 21 1,193 26 2,733 23 3,657 27 Japan 313 8 455 10 935 8 1,373 10 Rest of world 65 2 96 2 191 2 197 1 Total revenue $ 4,151 100 % $ 4,532 100 % $ 11,634 100 % $ 13,442 100 % (a) Revenue from end customers headquartered in Germany was 11% and 13% in the third quarters of 2024 and 2023, respectively, and 12% and 13% in the first nine months of 2024 and 2023, respectively.

Basis of presentation and signi

Basis of presentation and significant accounting policies and practices	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation and significant accounting policies and practices	Basis of presentation and significant accounting policies and practices Basis of presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and on the same basis as the audited financial statements included in our annual report on Form 10-K for the year ended December 31, 2023. The Consolidated Statements of Income, Comprehensive Income and Cash Flows for the periods ended September 30, 2024 and 2023, and the Consolidated Balance Sheet as of September 30, 2024, are not audited but reflect all adjustments that are of a normal recurring nature and are necessary for a fair statement of the results of the periods shown. Certain information and note disclosures normally included in annual consolidated financial statements have been omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Because the consolidated interim financial statements do not include all of the information and notes required by GAAP for a complete set of financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in our annual report on Form 10-K for the year ended December 31, 2023. The results for the three- and nine-month periods are not necessarily indicative of a full year’s results. Significant accounting policies and practices Earnings per share (EPS) We use the two-class method for calculating EPS because the restricted stock units (RSUs) we grant are participating securities containing nonforfeitable rights to receive dividend equivalents. Under the two-class method, a portion of net income is allocated to RSUs and excluded from the calculation of income allocated to common stock. Computation and reconciliation of earnings per common share are as follows: For Three Months Ended September 30, 2024 2023 Net Income Shares EPS Net Income Shares EPS Basic EPS: Net income $ 1,362 $ 1,709 Income allocated to RSUs (7) (9) Income allocated to common stock $ 1,355 913 $ 1.48 $ 1,700 908 $ 1.87 Dilutive effect of stock compensation plans 7 8 Diluted EPS: Net income $ 1,362 $ 1,709 Income allocated to RSUs (7) (10) Income allocated to common stock $ 1,355 920 $ 1.47 $ 1,699 916 $ 1.85 For Nine Months Ended September 30, 2024 2023 Net Income Shares EPS Net Income Shares EPS Basic EPS: Net income $ 3,594 $ 5,139 Income allocated to RSUs (18) (27) Income allocated to common stock $ 3,576 912 $ 3.92 $ 5,112 908 $ 5.63 Dilutive effect of stock compensation plans 7 8 Diluted EPS: Net income $ 3,594 $ 5,139 Income allocated to RSUs (18) (26) Income allocated to common stock $ 3,576 919 $ 3.89 $ 5,113 916 $ 5.58 Potentially dilutive securities representing 3 million and 9 million shares of common stock that were outstanding during the third quarters of 2024 and 2023, respectively, and 9 million and 9 million shares outstanding during the first nine months of 2024 and 2023, respectively, were excluded from the computation of diluted earnings per common share during these periods because their effect would have been anti-dilutive. Derivatives and hedging We use derivative financial instruments to manage exposure to foreign exchange risk. These instruments are primarily forward foreign currency exchange contracts, which are used as economic hedges to reduce the earnings impact that exchange rate fluctuations may have on our non-U.S. dollar net balance sheet exposures. Gains and losses from changes in the fair value of these forward foreign currency exchange contracts are credited or charged to OI&E. We do not apply hedge accounting to our foreign currency derivative instruments. We are exposed to variability in compensation charges related to certain deferred compensation obligations to employees. We use total return swaps to economically hedge this exposure and offset the related compensation expense, recognizing changes in the value of the swaps and the related deferred compensation liabilities in SG&A. In connection with the issuance of long-term debt, we may use financial derivatives such as treasury-rate lock agreements that are recognized in AOCI and amortized over the life of the related debt. The results of these derivative transactions were not material. We do not use derivatives for speculative or trading purposes. Fair values of financial instruments The fair values of our derivative financial instruments were not material as of September 30, 2024. Our investments in cash equivalents, short-term investments and certain long-term investments, as well as our deferred compensation liabilities, are carried at fair value. The carrying values for other current financial assets and liabilities, such as accounts receivable and accounts payable, approximate fair value due to the short maturity of such instruments. As of September 30, 2024, the carrying value of long-term debt, including the current portion, was $13.89 billion, and the estimated fair value was $13.46 billion. The estimated fair value is measured using broker-dealer quotes, which are Level 2 inputs. See Note 4 for a description of fair value and the definition of Level 2 inputs.

Income taxes

Income taxes	9 Months Ended
Income taxes	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Provision for income taxes is based on the following: For Three Months Ended For Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Taxes calculated using the estimated annual effective tax rate $ 227 $ 229 $ 573 $ 794 Discrete tax items (35) (16) (73) (63) Provision for income taxes $ 192 $ 213 $ 500 $ 731 Effective tax rate 12 % 11 % 12 % 12 % The effective tax rate differs from the 21% U.S. statutory corporate tax rate due to the effect of U.S. tax benefits.

Valuation of debt and equity in

Valuation of debt and equity investments and certain liabilities	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Valuation of debt and equity investments and certain liabilities	Valuation of debt and equity investments and certain liabilities Investments measured at fair value Money market funds, debt investments and mutual funds are stated at fair value, which is generally based on market prices or broker quotes. We classify all debt investments as available-for-sale. See Fair-value considerations . Unrealized gains and losses are recorded as an increase or decrease, net of taxes, in AOCI on our Consolidated Balance Sheets, and any credit losses are recorded as an allowance for credit losses with an offset recognized in OI&E in our Consolidated Statements of Income. Our mutual funds hold a variety of debt and equity investments intended to generate returns that offset changes in certain deferred compensation liabilities. We record changes in the fair value of these mutual funds and the related deferred compensation liabilities in SG&A. Other investments Our other investments include equity-method investments and nonmarketable investments, which are not measured at fair value. These investments consist of interests in venture capital funds and other nonmarketable securities. Gains and losses from equity-method investments are recognized in OI&E based on our ownership share of the investee’s financial results. Nonmarketable securities are measured at cost with adjustments for observable changes in price or impairments. Gains and losses on nonmarketable investments are recognized in OI&E. Details of our investments are as follows: September 30, 2024 December 31, 2023 Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash and Cash Equivalents Short-Term Investments Long-Term Investments Measured at fair value: Money market funds $ 515 $ — $ — $ 1,068 $ — $ — Corporate obligations 461 1,199 — 349 1,605 — U.S. government and agency securities 747 4,667 — 696 3,808 — Non-U.S. government and agency securities 150 297 — 50 198 — Mutual funds — — 11 — — 12 Total 1,873 6,163 11 2,163 5,611 12 Other measurement basis: Equity-method investments — — 11 — — 17 Nonmarketable investments — — 4 — — 5 Total — — 15 — — 22 Cash on hand 716 — — 801 — — Total $ 2,589 $ 6,163 $ 26 $ 2,964 $ 5,611 $ 34 As of September 30, 2024, and December 31, 2023, unrealized gains and losses associated with our debt investments were not material. We did not recognize any credit losses related to debt investments for the first nine months of 2024 and 2023. The following table presents the aggregate maturities of our available-for-sale debt investments as of September 30, 2024: Fair Value One year or less $ 6,493 One to two years 1,028 Proceeds from sales, redemptions and maturities of short-term available-for-sale investments were $2.70 billion and $2.89 billion for the third quarters of 2024 and 2023, respectively, and $8.46 billion and $9.98 billion for the first nine months of 2024 and 2023, respectively. Gross realized gains and losses from these sales were not material. Fair-value considerations We measure and report certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three-level hierarchy described below indicates the extent and level of judgment used to estimate fair-value measurements. • Level 1 – Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities as of the reporting date. • Level 2 – Uses inputs other than Level 1 that are either directly or indirectly observable as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data. We utilize a third-party data service to provide Level 2 valuations. We verify these valuations for reasonableness relative to unadjusted quotes obtained from brokers or dealers based on observable prices for similar assets in active markets. • Level 3 – Uses inputs that are unobservable, supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models that utilize management estimates of market participant assumptions. As of September 30, 2024, and December 31, 2023, we had no Level 3 assets or liabilities. The following are our assets and liabilities that were accounted for at fair value on a recurring basis. These tables do not include cash on hand, assets held by our postretirement plans, or assets and liabilities that are measured at historical cost or any basis other than fair value. September 30, 2024 December 31, 2023 Level 1 Level 2 Total Level 1 Level 2 Total Assets: Money market funds $ 515 $ — $ 515 $ 1,068 $ — $ 1,068 Corporate obligations — 1,660 1,660 — 1,954 1,954 U.S. government and agency securities 3,021 2,393 5,414 3,618 886 4,504 Non-U.S. government and agency securities — 447 447 — 248 248 Mutual funds 11 — 11 12 — 12 Total assets $ 3,547 $ 4,500 $ 8,047 $ 4,698 $ 3,088 $ 7,786 Liabilities: Deferred compensation $ 435 $ — $ 435 $ 393 $ — $ 393 Total liabilities $ 435 $ — $ 435 $ 393 $ — $ 393

Postretirement benefit plans

Postretirement benefit plans	9 Months Ended
Postretirement benefit plans	Sep. 30, 2024
Retirement Benefits [Abstract]
Postretirement benefit plans	Postretirement benefit plans Expenses related to defined benefit and retiree health care benefit plans are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit For Three Months Ended September 30, 2024 2023 2024 2023 2024 2023 Service cost $ 2 $ 2 $ — $ — $ 4 $ 4 Interest cost 7 7 4 4 15 14 Expected return on plan assets (7) (6) (4) (4) (22) (16) Recognized net actuarial losses (gains) 1 2 (1) (1) 3 3 Amortization of prior service cost (credit) — — — — 1 1 Net periodic benefit costs (credits) 3 5 (1) (1) 1 6 Total, including other postretirement losses (gains) $ 3 $ 5 $ (1) $ (1) $ 1 $ 6 U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit For Nine Months Ended September 30, 2024 2023 2024 2023 2024 2023 Service cost $ 6 $ 6 $ 1 $ 1 $ 12 $ 12 Interest cost 19 21 10 11 42 43 Expected return on plan assets (18) (17) (13) (13) (60) (48) Recognized net actuarial losses (gains) 3 5 (2) (4) 9 9 Amortization of prior service cost (credit) — — — — 1 1 Net periodic benefit costs (credits) 10 15 (4) (5) 4 17 Settlement losses — 1 — — — 1 Total, including other postretirement losses (gains) $ 10 $ 16 $ (4) $ (5) $ 4 $ 18

Debt and lines of credit

Debt and lines of credit	9 Months Ended
Debt and lines of credit	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt and lines of credit	Debt and lines of credit Short-term borrowings We maintain a line of credit to provide additional liquidity through bank loans and, if necessary, to support commercial paper borrowings. As of September 30, 2024, the aforementioned line of credit was a variable-rate, revolving credit facility from a consortium of investment-grade banks that allows us to borrow up to $1 billion until March 2025. The interest rate on borrowings under this credit facility, if drawn, is indexed to the applicable Term Secured Overnight Financing Rate (Term SOFR). As of September 30, 2024, our credit facility was undrawn, and we had no commercial paper outstanding. Long-term debt In May 2024, we retired $300 million of maturing debt. In February 2024, we issued five series of senior unsecured notes for an aggregate principal amount of $3.00 billion, consisting of: • $650 million of 4.60% notes due in 2027; • $650 million of 4.60% notes due in 2029; • $600 million of 4.85% notes due in 2034; • $750 million of 5.15% notes due in 2054; and • $350 million further issuance of existing 5.05% notes due in 2063. We incurred $16 million of issuance and other related costs. The proceeds of the offering were $2.98 billion, net of the original issuance discounts, which will be used for general corporate purposes. Long-term debt outstanding is as follows: September 30, December 31, 2024 2023 Notes due 2024 at 2.625% $ — $ 300 Notes due 2024 at 4.70% 300 300 Notes due 2025 at 1.375% 750 750 Notes due 2026 at 1.125% 500 500 Notes due 2027 at 4.60% 650 — Notes due 2027 at 2.90% 500 500 Notes due 2028 at 4.60% 700 700 Notes due 2029 at 4.60% 650 — Notes due 2029 at 2.25% 750 750 Notes due 2030 at 1.75% 750 750 Notes due 2031 at 1.90% 500 500 Notes due 2032 at 3.65% 400 400 Notes due 2033 at 4.90% 950 950 Notes due 2034 at 4.85% 600 — Notes due 2039 at 3.875% 750 750 Notes due 2048 at 4.15% 1,500 1,500 Notes due 2051 at 2.70% 500 500 Notes due 2052 at 4.10% 300 300 Notes due 2053 at 5.00% 650 650 Notes due 2054 at 5.15% 750 — Notes due 2063 at 5.05% 1,550 1,200 Total debt 14,000 11,300 Net unamortized discounts, premiums and issuance costs (107) (77) Total debt, including net unamortized discounts, premiums and issuance costs 13,893 11,223 Current portion of long-term debt (1,049) (599) Long-term debt $ 12,844 $ 10,624 Interest and debt expense was $131 million and $98 million for the third quarters of 2024 and 2023, respectively, and $378 million and $255 million for the first nine months of 2024 and 2023, respectively. This was net of the amortized discounts, premiums, issuance and other related costs. Capitalized interest was $5 million and $3 million for the third quarters of 2024 and 2023, respectively, and $16 million and $8 million for the first nine months of 2024 and 2023, respectively.

Stockholders' equity

Stockholders' equity	9 Months Ended
Stockholders' equity	Sep. 30, 2024
Equity [Abstract]
Stockholders’ equity	Stockholders’ equity Changes in equity are as follows: Common Stock Paid-in Capital Retained Earnings Treasury Common Stock AOCI Balance, December 31, 2023 $ 1,741 $ 3,362 $ 52,283 $ (40,284) $ (205) 2024 Net income — — 1,105 — — Dividends declared and paid ($1.30 per share) — — (1,183) — — Common stock issued for stock-based awards — (29) — 94 — Stock repurchases — — — (3) — Stock compensation — 106 — — — Other comprehensive income (loss), net of taxes — — — — 2 Dividend equivalents on RSUs — — (7) — — Other — — 1 — — Balance, March 31, 2024 1,741 3,439 52,199 (40,193) (203) Net income — — 1,127 — — Dividends declared and paid ($1.30 per share) — — (1,185) — — Common stock issued for stock-based awards — 111 — 137 — Stock repurchases — — — (72) — Stock compensation — 116 — — — Other comprehensive income (loss), net of taxes — — — — 3 Dividend equivalents on RSUs — — (6) — — Balance, June 30, 2024 1,741 3,666 52,135 (40,128) (200) Net income — — 1,362 — — Dividends declared and paid ($1.30 per share) — — (1,187) — — Common stock issued for stock-based awards — 62 — 55 — Stock repurchases — — — (322) — Stock compensation — 87 — — — Other comprehensive income (loss), net of taxes — — — — 5 Dividend equivalents on RSUs — — (6) — — Other — (2) — — — Balance, September 30, 2024 $ 1,741 $ 3,813 $ 52,304 $ (40,395) $ (195) Common Stock Paid-in Capital Retained Earnings Treasury Common Stock AOCI Balance, December 31, 2022 $ 1,741 $ 2,951 $ 50,353 $ (40,214) $ (254) 2023 Net income — — 1,708 — — Dividends declared and paid ($1.24 per share) — — (1,125) — — Common stock issued for stock-based awards — (37) — 118 — Stock repurchases — — — (96) — Stock compensation — 104 — — — Other comprehensive income (loss), net of taxes — — — — 2 Dividend equivalents on RSUs — — (6) — — Other — (2) — — — Balance, March 31, 2023 1,741 3,016 50,930 (40,192) (252) Net income — — 1,722 — — Dividends declared and paid ($1.24 per share) — — (1,125) — — Common stock issued for stock-based awards — 36 — 29 — Stock repurchases — — — (77) — Stock compensation — 111 — — — Other comprehensive income (loss), net of taxes — — — — 6 Dividend equivalents on RSUs — — (5) — — Balance, June 30, 2023 1,741 3,163 51,522 (40,240) (246) Net income — — 1,709 — — Dividends declared and paid ($1.24 per share) — — (1,126) — — Common stock issued for stock-based awards — 38 — 35 — Stock repurchases — — — (48) — Stock compensation — 79 — — — Other comprehensive income (loss), net of taxes — — — — 11 Dividend equivalents on RSUs — — (6) — — Other — — (1) — — Balance, September 30, 2023 $ 1,741 $ 3,280 $ 52,098 $ (40,253) $ (235)

Contingencies

Contingencies	9 Months Ended
Contingencies	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Indemnification guarantees We routinely sell products with an intellectual property indemnification included in the terms of sale. Historically, we have had only minimal, infrequent losses associated with these indemnities. Consequently, we cannot reasonably estimate any future liabilities that may result. Warranty costs/product liabilities Our stated warranties for semiconductor products obligate us to repair, replace or credit the purchase price of a covered product back to the buyer. Product claim consideration may exceed the price of our products. Historically, we have experienced a low rate of payments on product claims. Although we cannot predict the likelihood or amount of any future claims, we do not believe they will have a material adverse effect on our consolidated financial statements. We accrue for known product-related claims if a loss is probable and can be reasonably estimated. During the periods presented, there have been no material accruals or payments regarding product warranty or product liability. General We are subject to various legal and administrative proceedings. Although it is not possible to predict the outcome of these matters, we believe that the results of these proceedings will not have a material adverse effect on our consolidated financial statements.

Supplemental financial informat

Supplemental financial information	9 Months Ended
Supplemental financial information	Sep. 30, 2024
Disclosure Text Block Supplement [Abstract]
Supplemental financial information	Supplemental financial information Restructuring charges/other During the first nine months of 2024, restructuring charges/other was a credit of $124 million primarily due to a gain on the sale of a property. Prepaid expenses and other current assets September 30, December 31, 2024 2023 U.S. CHIPS and Science Act investment tax credit $ 621 $ 497 Other 341 264 Total $ 962 $ 761 Other long-term assets September 30, December 31, 2024 2023 U.S. CHIPS and Science Act investment tax credit $ 806 $ 859 Operating lease right-of-use assets 800 579 Other 325 274 Total $ 1,931 $ 1,712 Other long-term liabilities September 30, December 31, 2024 2023 Operating lease liabilities $ 681 $ 478 Other 671 858 Total $ 1,352 $ 1,336 Details on amounts reclassified out of accumulated other comprehensive income (loss), net of taxes, to net income Our Consolidated Statements of Comprehensive Income include items that have been recognized within net income during the third quarters and first nine months of 2024 and 2023. The table below details where these transactions are recorded in our Consolidated Statements of Income. For Three Months Ended For Nine Months Ended Impact to Related Statement of Income Lines September 30, September 30, 2024 2023 2024 2023 Net actuarial losses of defined benefit plans: Recognized net actuarial losses and settlement losses (a) $ 3 $ 4 $ 10 $ 12 Decrease to OI&E Tax effect (1) (1) (3) (3) Decrease to provision for income taxes Recognized within net income, net of taxes $ 2 $ 3 $ 7 $ 9 Decrease to net income Prior service cost (credit) of defined benefit plans: Amortization of prior service cost (credit) (a) $ 1 $ 1 $ 1 $ 1 Decrease (increase) to OI&E Tax effect — — — — (Decrease) increase to provision for income taxes Recognized within net income, net of taxes $ 1 $ 1 $ 1 $ 1 Decrease (increase) to net income (a) Detailed in Note 5 Effect on shares outstanding and treasury shares The following table reflects the changes in treasury shares: 2024 Balance, January 1 832 Repurchases — Shares issued for stock compensation (1) Balance, March 31 831 Repurchases — Shares issued for stock compensation (3) Balance, June 30 828 Repurchases 2 Shares issued for stock compensation (1) Balance, September 30 829

Basis of presentation and sig_2

Basis of presentation and significant accounting policies and practices (Policies)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and on the same basis as the audited financial statements included in our annual report on Form 10-K for the year ended December 31, 2023. The Consolidated Statements of Income, Comprehensive Income and Cash Flows for the periods ended September 30, 2024 and 2023, and the Consolidated Balance Sheet as of September 30, 2024, are not audited but reflect all adjustments that are of a normal recurring nature and are necessary for a fair statement of the results of the periods shown. Certain information and note disclosures normally included in annual consolidated financial statements have been omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Because the consolidated interim financial statements do not include all of the information and notes required by GAAP for a complete set of financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in our annual report on Form 10-K for the year ended December 31, 2023. The results for the three- and nine-month periods are not necessarily indicative of a full year’s results.
Earnings per share (EPS)	Earnings per share (EPS) We use the two-class method for calculating EPS because the restricted stock units (RSUs) we grant are participating securities containing nonforfeitable rights to receive dividend equivalents. Under the two-class method, a portion of net income is allocated to RSUs and excluded from the calculation of income allocated to common stock.
Derivatives and hedging	Derivatives and hedging We use derivative financial instruments to manage exposure to foreign exchange risk. These instruments are primarily forward foreign currency exchange contracts, which are used as economic hedges to reduce the earnings impact that exchange rate fluctuations may have on our non-U.S. dollar net balance sheet exposures. Gains and losses from changes in the fair value of these forward foreign currency exchange contracts are credited or charged to OI&E. We do not apply hedge accounting to our foreign currency derivative instruments. We are exposed to variability in compensation charges related to certain deferred compensation obligations to employees. We use total return swaps to economically hedge this exposure and offset the related compensation expense, recognizing changes in the value of the swaps and the related deferred compensation liabilities in SG&A. In connection with the issuance of long-term debt, we may use financial derivatives such as treasury-rate lock agreements that are recognized in AOCI and amortized over the life of the related debt. The results of these derivative transactions were not material. We do not use derivatives for speculative or trading purposes.
Fair values of financial instruments	Fair values of financial instruments
Investments measured at fair value	Investments measured at fair value Money market funds, debt investments and mutual funds are stated at fair value, which is generally based on market prices or broker quotes. We classify all debt investments as available-for-sale. See Fair-value considerations . Unrealized gains and losses are recorded as an increase or decrease, net of taxes, in AOCI on our Consolidated Balance Sheets, and any credit losses are recorded as an allowance for credit losses with an offset recognized in OI&E in our Consolidated Statements of Income. Our mutual funds hold a variety of debt and equity investments intended to generate returns that offset changes in certain deferred compensation liabilities. We record changes in the fair value of these mutual funds and the related deferred compensation liabilities in SG&A. Other investments Our other investments include equity-method investments and nonmarketable investments, which are not measured at fair value. These investments consist of interests in venture capital funds and other nonmarketable securities. Gains and losses from equity-method investments are recognized in OI&E based on our ownership share of the investee’s financial results. Nonmarketable securities are measured at cost with adjustments for observable changes in price or impairments. Gains and losses on nonmarketable investments are recognized in OI&E.
Fair value considerations	Fair-value considerations We measure and report certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three-level hierarchy described below indicates the extent and level of judgment used to estimate fair-value measurements. • Level 1 – Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities as of the reporting date. • Level 2 – Uses inputs other than Level 1 that are either directly or indirectly observable as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data. We utilize a third-party data service to provide Level 2 valuations. We verify these valuations for reasonableness relative to unadjusted quotes obtained from brokers or dealers based on observable prices for similar assets in active markets. • Level 3 – Uses inputs that are unobservable, supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models that utilize management estimates of market participant assumptions. As of September 30, 2024, and December 31, 2023, we had no Level 3 assets or liabilities.
Indemnification guarantees and warranty costs/product liabilities	Indemnification guarantees We routinely sell products with an intellectual property indemnification included in the terms of sale. Historically, we have had only minimal, infrequent losses associated with these indemnities. Consequently, we cannot reasonably estimate any future liabilities that may result. Warranty costs/product liabilities

Description of business, incl_2

Description of business, including segment and geographic area information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Information	Segment information For Three Months Ended For Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenue: Analog $ 3,223 $ 3,353 $ 8,987 $ 9,920 Embedded Processing 653 890 1,920 2,616 Other 275 289 727 906 Total revenue $ 4,151 $ 4,532 $ 11,634 $ 13,442 Operating profit: Analog $ 1,316 $ 1,504 $ 3,371 $ 4,541 Embedded Processing 109 258 294 813 Other (a) 129 130 423 444 Total operating profit $ 1,554 $ 1,892 $ 4,088 $ 5,798 (a) Includes restructuring charges/other
Schedule of Geographic Area Information	Geographic area information Our estimate for revenue based on the geographic location of our end customers’ headquarters, which represents where critical decisions are made, is as follows: For Three Months Ended For Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenue: United States $ 1,639 39 % $ 1,541 34 % $ 4,335 37 % $ 4,391 33 % China 823 20 813 18 2,191 19 2,561 19 Rest of Asia 431 10 434 10 1,249 11 1,263 10 Europe, Middle East and Africa (a) 880 21 1,193 26 2,733 23 3,657 27 Japan 313 8 455 10 935 8 1,373 10 Rest of world 65 2 96 2 191 2 197 1 Total revenue $ 4,151 100 % $ 4,532 100 % $ 11,634 100 % $ 13,442 100 % (a) Revenue from end customers headquartered in Germany was 11% and 13% in the third quarters of 2024 and 2023, respectively, and 12% and 13% in the first nine months of 2024 and 2023, respectively.

Basis of presentation and sig_3

Basis of presentation and significant accounting policies and practices (Tables)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Earnings Per Share	Computation and reconciliation of earnings per common share are as follows: For Three Months Ended September 30, 2024 2023 Net Income Shares EPS Net Income Shares EPS Basic EPS: Net income $ 1,362 $ 1,709 Income allocated to RSUs (7) (9) Income allocated to common stock $ 1,355 913 $ 1.48 $ 1,700 908 $ 1.87 Dilutive effect of stock compensation plans 7 8 Diluted EPS: Net income $ 1,362 $ 1,709 Income allocated to RSUs (7) (10) Income allocated to common stock $ 1,355 920 $ 1.47 $ 1,699 916 $ 1.85 For Nine Months Ended September 30, 2024 2023 Net Income Shares EPS Net Income Shares EPS Basic EPS: Net income $ 3,594 $ 5,139 Income allocated to RSUs (18) (27) Income allocated to common stock $ 3,576 912 $ 3.92 $ 5,112 908 $ 5.63 Dilutive effect of stock compensation plans 7 8 Diluted EPS: Net income $ 3,594 $ 5,139 Income allocated to RSUs (18) (26) Income allocated to common stock $ 3,576 919 $ 3.89 $ 5,113 916 $ 5.58

Income taxes (Tables)

Income taxes (Tables)	9 Months Ended
Income taxes (Tables)	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	Provision for income taxes is based on the following: For Three Months Ended For Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Taxes calculated using the estimated annual effective tax rate $ 227 $ 229 $ 573 $ 794 Discrete tax items (35) (16) (73) (63) Provision for income taxes $ 192 $ 213 $ 500 $ 731 Effective tax rate 12 % 11 % 12 % 12 %

Valuation of debt and equity _2

Valuation of debt and equity investments and certain liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Investments	Details of our investments are as follows: September 30, 2024 December 31, 2023 Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash and Cash Equivalents Short-Term Investments Long-Term Investments Measured at fair value: Money market funds $ 515 $ — $ — $ 1,068 $ — $ — Corporate obligations 461 1,199 — 349 1,605 — U.S. government and agency securities 747 4,667 — 696 3,808 — Non-U.S. government and agency securities 150 297 — 50 198 — Mutual funds — — 11 — — 12 Total 1,873 6,163 11 2,163 5,611 12 Other measurement basis: Equity-method investments — — 11 — — 17 Nonmarketable investments — — 4 — — 5 Total — — 15 — — 22 Cash on hand 716 — — 801 — — Total $ 2,589 $ 6,163 $ 26 $ 2,964 $ 5,611 $ 34
Schedule of Aggregate Maturities of Available-for-sale Debt Investments	The following table presents the aggregate maturities of our available-for-sale debt investments as of September 30, 2024: Fair Value One year or less $ 6,493 One to two years 1,028
Schedule of Assets and Liabilities Accounted for at Fair Value	The following are our assets and liabilities that were accounted for at fair value on a recurring basis. These tables do not include cash on hand, assets held by our postretirement plans, or assets and liabilities that are measured at historical cost or any basis other than fair value. September 30, 2024 December 31, 2023 Level 1 Level 2 Total Level 1 Level 2 Total Assets: Money market funds $ 515 $ — $ 515 $ 1,068 $ — $ 1,068 Corporate obligations — 1,660 1,660 — 1,954 1,954 U.S. government and agency securities 3,021 2,393 5,414 3,618 886 4,504 Non-U.S. government and agency securities — 447 447 — 248 248 Mutual funds 11 — 11 12 — 12 Total assets $ 3,547 $ 4,500 $ 8,047 $ 4,698 $ 3,088 $ 7,786 Liabilities: Deferred compensation $ 435 $ — $ 435 $ 393 $ — $ 393 Total liabilities $ 435 $ — $ 435 $ 393 $ — $ 393

Postretirement benefit plans (T

Postretirement benefit plans (Tables)	9 Months Ended
Postretirement benefit plans (Tables)	Sep. 30, 2024
Retirement Benefits [Abstract]
Schedule of Expense Related to Defined Benefit and Retiree Health Care Benefit Plans	Expenses related to defined benefit and retiree health care benefit plans are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit For Three Months Ended September 30, 2024 2023 2024 2023 2024 2023 Service cost $ 2 $ 2 $ — $ — $ 4 $ 4 Interest cost 7 7 4 4 15 14 Expected return on plan assets (7) (6) (4) (4) (22) (16) Recognized net actuarial losses (gains) 1 2 (1) (1) 3 3 Amortization of prior service cost (credit) — — — — 1 1 Net periodic benefit costs (credits) 3 5 (1) (1) 1 6 Total, including other postretirement losses (gains) $ 3 $ 5 $ (1) $ (1) $ 1 $ 6 U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit For Nine Months Ended September 30, 2024 2023 2024 2023 2024 2023 Service cost $ 6 $ 6 $ 1 $ 1 $ 12 $ 12 Interest cost 19 21 10 11 42 43 Expected return on plan assets (18) (17) (13) (13) (60) (48) Recognized net actuarial losses (gains) 3 5 (2) (4) 9 9 Amortization of prior service cost (credit) — — — — 1 1 Net periodic benefit costs (credits) 10 15 (4) (5) 4 17 Settlement losses — 1 — — — 1 Total, including other postretirement losses (gains) $ 10 $ 16 $ (4) $ (5) $ 4 $ 18

Debt and lines of credit (Table

Debt and lines of credit (Tables)	9 Months Ended
Debt and lines of credit (Tables)	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt outstanding is as follows: September 30, December 31, 2024 2023 Notes due 2024 at 2.625% $ — $ 300 Notes due 2024 at 4.70% 300 300 Notes due 2025 at 1.375% 750 750 Notes due 2026 at 1.125% 500 500 Notes due 2027 at 4.60% 650 — Notes due 2027 at 2.90% 500 500 Notes due 2028 at 4.60% 700 700 Notes due 2029 at 4.60% 650 — Notes due 2029 at 2.25% 750 750 Notes due 2030 at 1.75% 750 750 Notes due 2031 at 1.90% 500 500 Notes due 2032 at 3.65% 400 400 Notes due 2033 at 4.90% 950 950 Notes due 2034 at 4.85% 600 — Notes due 2039 at 3.875% 750 750 Notes due 2048 at 4.15% 1,500 1,500 Notes due 2051 at 2.70% 500 500 Notes due 2052 at 4.10% 300 300 Notes due 2053 at 5.00% 650 650 Notes due 2054 at 5.15% 750 — Notes due 2063 at 5.05% 1,550 1,200 Total debt 14,000 11,300 Net unamortized discounts, premiums and issuance costs (107) (77) Total debt, including net unamortized discounts, premiums and issuance costs 13,893 11,223 Current portion of long-term debt (1,049) (599) Long-term debt $ 12,844 $ 10,624

Stockholders' equity (Tables)

Stockholders' equity (Tables)	9 Months Ended
Stockholders' equity (Tables)	Sep. 30, 2024
Equity [Abstract]
Schedule of Changes in Stockholders' Equity	Changes in equity are as follows: Common Stock Paid-in Capital Retained Earnings Treasury Common Stock AOCI Balance, December 31, 2023 $ 1,741 $ 3,362 $ 52,283 $ (40,284) $ (205) 2024 Net income — — 1,105 — — Dividends declared and paid ($1.30 per share) — — (1,183) — — Common stock issued for stock-based awards — (29) — 94 — Stock repurchases — — — (3) — Stock compensation — 106 — — — Other comprehensive income (loss), net of taxes — — — — 2 Dividend equivalents on RSUs — — (7) — — Other — — 1 — — Balance, March 31, 2024 1,741 3,439 52,199 (40,193) (203) Net income — — 1,127 — — Dividends declared and paid ($1.30 per share) — — (1,185) — — Common stock issued for stock-based awards — 111 — 137 — Stock repurchases — — — (72) — Stock compensation — 116 — — — Other comprehensive income (loss), net of taxes — — — — 3 Dividend equivalents on RSUs — — (6) — — Balance, June 30, 2024 1,741 3,666 52,135 (40,128) (200) Net income — — 1,362 — — Dividends declared and paid ($1.30 per share) — — (1,187) — — Common stock issued for stock-based awards — 62 — 55 — Stock repurchases — — — (322) — Stock compensation — 87 — — — Other comprehensive income (loss), net of taxes — — — — 5 Dividend equivalents on RSUs — — (6) — — Other — (2) — — — Balance, September 30, 2024 $ 1,741 $ 3,813 $ 52,304 $ (40,395) $ (195) Common Stock Paid-in Capital Retained Earnings Treasury Common Stock AOCI Balance, December 31, 2022 $ 1,741 $ 2,951 $ 50,353 $ (40,214) $ (254) 2023 Net income — — 1,708 — — Dividends declared and paid ($1.24 per share) — — (1,125) — — Common stock issued for stock-based awards — (37) — 118 — Stock repurchases — — — (96) — Stock compensation — 104 — — — Other comprehensive income (loss), net of taxes — — — — 2 Dividend equivalents on RSUs — — (6) — — Other — (2) — — — Balance, March 31, 2023 1,741 3,016 50,930 (40,192) (252) Net income — — 1,722 — — Dividends declared and paid ($1.24 per share) — — (1,125) — — Common stock issued for stock-based awards — 36 — 29 — Stock repurchases — — — (77) — Stock compensation — 111 — — — Other comprehensive income (loss), net of taxes — — — — 6 Dividend equivalents on RSUs — — (5) — — Balance, June 30, 2023 1,741 3,163 51,522 (40,240) (246) Net income — — 1,709 — — Dividends declared and paid ($1.24 per share) — — (1,126) — — Common stock issued for stock-based awards — 38 — 35 — Stock repurchases — — — (48) — Stock compensation — 79 — — — Other comprehensive income (loss), net of taxes — — — — 11 Dividend equivalents on RSUs — — (6) — — Other — — (1) — — Balance, September 30, 2023 $ 1,741 $ 3,280 $ 52,098 $ (40,253) $ (235)

Supplemental financial inform_2

Supplemental financial information (Tables)	9 Months Ended
Supplemental financial information (Tables)	Sep. 30, 2024
Disclosure Text Block Supplement [Abstract]
Schedule of Other Current Assets	Prepaid expenses and other current assets September 30, December 31, 2024 2023 U.S. CHIPS and Science Act investment tax credit $ 621 $ 497 Other 341 264 Total $ 962 $ 761
Schedule of Other Long-Term Assets	Other long-term assets September 30, December 31, 2024 2023 U.S. CHIPS and Science Act investment tax credit $ 806 $ 859 Operating lease right-of-use assets 800 579 Other 325 274 Total $ 1,931 $ 1,712
Schedule of Other Long-Term Liabilities	Other long-term liabilities September 30, December 31, 2024 2023 Operating lease liabilities $ 681 $ 478 Other 671 858 Total $ 1,352 $ 1,336
Schedule of Amounts Reclassified Out of AOCI to Net Income, Net of Taxes	The table below details where these transactions are recorded in our Consolidated Statements of Income. For Three Months Ended For Nine Months Ended Impact to Related Statement of Income Lines September 30, September 30, 2024 2023 2024 2023 Net actuarial losses of defined benefit plans: Recognized net actuarial losses and settlement losses (a) $ 3 $ 4 $ 10 $ 12 Decrease to OI&E Tax effect (1) (1) (3) (3) Decrease to provision for income taxes Recognized within net income, net of taxes $ 2 $ 3 $ 7 $ 9 Decrease to net income Prior service cost (credit) of defined benefit plans: Amortization of prior service cost (credit) (a) $ 1 $ 1 $ 1 $ 1 Decrease (increase) to OI&E Tax effect — — — — (Decrease) increase to provision for income taxes Recognized within net income, net of taxes $ 1 $ 1 $ 1 $ 1 Decrease (increase) to net income (a) Detailed in Note 5
Schedule of Effect of Shares Outstanding and Treasury Shares	Effect on shares outstanding and treasury shares The following table reflects the changes in treasury shares: 2024 Balance, January 1 832 Repurchases — Shares issued for stock compensation (1) Balance, March 31 831 Repurchases — Shares issued for stock compensation (3) Balance, June 30 828 Repurchases 2 Shares issued for stock compensation (1) Balance, September 30 829

Description of business, incl_3

Description of business, including segment and geographic area information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2024 reportable_segment productLine
Segment Reporting [Abstract]
Number of reportable segments \| reportable_segment	2
Number of product lines, Analog Segment \| productLine	2

Description of business, incl_4

Description of business, including segment and geographic area information - Segment Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total revenue		$ 4,151	$ 4,532	$ 11,634	$ 13,442
Total operating profit		1,554	1,892	4,088	5,798
Analog
Segment Reporting Information [Line Items]
Total revenue		3,223	3,353	8,987	9,920
Total operating profit		1,316	1,504	3,371	4,541
Embedded Processing
Segment Reporting Information [Line Items]
Total revenue		653	890	1,920	2,616
Total operating profit		109	258	294	813
Other
Segment Reporting Information [Line Items]
Total revenue		275	289	727	906
Total operating profit	[1]	$ 129	$ 130	$ 423	$ 444

[1] Includes restructuring charges/other

Description of business, incl_5

Description of business, including segment and geographic area information - Geographic Area Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total revenue		$ 4,151	$ 4,532	$ 11,634	$ 13,442
Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Total revenue		$ 4,151	$ 4,532	$ 11,634	$ 13,442
Concentration risk, percentage		100%	100%	100%	100%
United States \| Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Total revenue		$ 1,639	$ 1,541	$ 4,335	$ 4,391
Concentration risk, percentage		39%	34%	37%	33%
China \| Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Total revenue		$ 823	$ 813	$ 2,191	$ 2,561
Concentration risk, percentage		20%	18%	19%	19%
Rest of Asia \| Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Total revenue		$ 431	$ 434	$ 1,249	$ 1,263
Concentration risk, percentage		10%	10%	11%	10%
Europe, Middle East and Africa \| Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Total revenue	[1]	$ 880	$ 1,193	$ 2,733	$ 3,657
Concentration risk, percentage	[1]	21%	26%	23%	27%
Japan \| Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Total revenue		$ 313	$ 455	$ 935	$ 1,373
Concentration risk, percentage		8%	10%	8%	10%
Rest of world \| Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Total revenue		$ 65	$ 96	$ 191	$ 197
Concentration risk, percentage		2%	2%	2%	1%
Germany \| Revenue from Contract with Customer, Product and Service Benchmark \| Geographic Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk, percentage		11%	13%	12%	13%

[1] Revenue from end customers headquartered in Germany was 11% and 13% in the third quarters of 2024 and 2023, respectively, and 12% and 13% in the first nine months of 2024 and 2023, respectively.

Basis of presentation and sig_4

Basis of presentation and significant accounting policies and practices - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Basic EPS:
Net income	$ 1,362	$ 1,709	$ 3,594	$ 5,139
Income allocated to RSUs	(7)	(9)	(18)	(27)
Income allocated to common stock	$ 1,355	$ 1,700	$ 3,576	$ 5,112
Weighted average number of shares outstanding, basic (in shares)	913	908	912	908
Basic (in dollars per share)	$ 1.48	$ 1.87	$ 3.92	$ 5.63
Dilutive effect of stock compensation plans (in shares)	7	8	7	8
Diluted EPS:
Net income	$ 1,362	$ 1,709	$ 3,594	$ 5,139
Income allocated to RSUs	(7)	(10)	(18)	(26)
Income allocated to common stock for diluted EPS	$ 1,355	$ 1,699	$ 3,576	$ 5,113
Weighted average number of shares outstanding, diluted (in shares)	920	916	919	916
Diluted (in dollars per share)	$ 1.47	$ 1.85	$ 3.89	$ 5.58

Basis of presentation and sig_5

Basis of presentation and significant accounting policies and practices - Additional Information (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Antidilutive securities excluded from computation of earnings per share, Amount (in shares)	3	9	9	9
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, carrying value	$ 13,893		$ 13,893		$ 11,223
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, estimated fair value	$ 13,460		$ 13,460

Income taxes - Provision for In

Income taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Taxes calculated using the estimated annual effective tax rate	$ 227	$ 229	$ 573	$ 794
Discrete tax items	(35)	(16)	(73)	(63)
Provision for income taxes	$ 192	$ 213	$ 500	$ 731
Effective tax rate	12%	11%	12%	12%

Income taxes - Additional Infor

Income taxes - Additional Information (Details)	9 Months Ended
Income taxes - Additional Information (Details)	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Statutory corporate tax rate	21%

Valuation of debt and equity _3

Valuation of debt and equity investments and certain liabilities - Investments at Fair Value (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	$ 2,589	$ 2,964
Short-term investments	6,163	5,611
Long-Term Investments	26	34
Measured at fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	1,873	2,163
Short-term investments	6,163	5,611
Long-Term Investments	11	12
Other measurement basis
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	0	0
Short-term investments	0	0
Long-Term Investments	15	22
Money market funds \| Measured at fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	515	1,068
Short-term investments	0	0
Long-Term Investments	0	0
Corporate obligations \| Measured at fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	461	349
Short-term investments	1,199	1,605
Long-Term Investments	0	0
U.S. government and agency securities \| Measured at fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	747	696
Short-term investments	4,667	3,808
Long-Term Investments	0	0
Non-U.S. government and agency securities \| Measured at fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	150	50
Short-term investments	297	198
Long-Term Investments	0	0
Mutual funds \| Measured at fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	0	0
Short-term investments	0	0
Long-Term Investments	11	12
Equity-method investments \| Other measurement basis
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	0	0
Short-term investments	0	0
Long-Term Investments	11	17
Nonmarketable investments \| Other measurement basis
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	0	0
Short-term investments	0	0
Long-Term Investments	4	5
Cash on hand \| Other measurement basis
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents	716	801
Short-term investments	0	0
Long-Term Investments	$ 0	$ 0

Valuation of debt and equity _4

Valuation of debt and equity investments and certain liabilities - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Credit losses related to available-for-sale investments			$ 0	$ 0
Proceeds from sales, redemptions and maturities of short-term available-for-sale investments	$ 2,700,000,000	$ 2,890,000,000	8,460,000,000	$ 9,980,000,000
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities, fair value	0		0		$ 0
Assets, fair value	$ 0		$ 0		$ 0

Valuation of debt and equity _5

Valuation of debt and equity investments and certain liabilities - Aggregate Liabilities of Our Available-for-Sale Debt Investments (Details) $ in Millions	Sep. 30, 2024 USD ($)
Fair Value Disclosures [Abstract]
One year or less	$ 6,493
One to two years	$ 1,028

Valuation of debt and equity _6

Valuation of debt and equity investments and certain liabilities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	$ 8,047	$ 7,786
Total liabilities fair value	435	393
Deferred compensation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities fair value	435	393
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	3,547	4,698
Total liabilities fair value	435	393
Level 1 \| Deferred compensation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities fair value	435	393
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	4,500	3,088
Total liabilities fair value	0	0
Level 2 \| Deferred compensation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities fair value	0	0
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	515	1,068
Money market funds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	515	1,068
Money market funds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	0	0
Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	1,660	1,954
Corporate obligations \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	0	0
Corporate obligations \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	1,660	1,954
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	5,414	4,504
U.S. government and agency securities \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	3,021	3,618
U.S. government and agency securities \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	2,393	886
Non-U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	447	248
Non-U.S. government and agency securities \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	0	0
Non-U.S. government and agency securities \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	447	248
Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	11	12
Mutual funds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	11	12
Mutual funds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets fair value	$ 0	$ 0

Postretirement benefit plans (D

Postretirement benefit plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
U.S. \| Defined benefit plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 2	$ 2	$ 6	$ 6
Interest cost	7	7	19	21
Expected return on plan assets	(7)	(6)	(18)	(17)
Recognized net actuarial losses (gains)	1	2	3	5
Amortization of prior service cost (credit)	0	0	0	0
Net periodic benefit costs (credits)	3	5	10	15
Settlement losses			0	1
Total, including other postretirement losses (gains)	3	5	10	16
U.S. \| Retiree health care plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	1	1
Interest cost	4	4	10	11
Expected return on plan assets	(4)	(4)	(13)	(13)
Recognized net actuarial losses (gains)	(1)	(1)	(2)	(4)
Amortization of prior service cost (credit)	0	0	0	0
Net periodic benefit costs (credits)	(1)	(1)	(4)	(5)
Settlement losses			0	0
Total, including other postretirement losses (gains)	(1)	(1)	(4)	(5)
Non-U.S. \| Defined benefit plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	4	4	12	12
Interest cost	15	14	42	43
Expected return on plan assets	(22)	(16)	(60)	(48)
Recognized net actuarial losses (gains)	3	3	9	9
Amortization of prior service cost (credit)	1	1	1	1
Net periodic benefit costs (credits)	1	6	4	17
Settlement losses			0	1
Total, including other postretirement losses (gains)	$ 1	$ 6	$ 4	$ 18

Debt and lines of credit - Addi

Debt and lines of credit - Additional Information (Details)	1 Months Ended		3 Months Ended		9 Months Ended
Debt and lines of credit - Additional Information (Details)	May 31, 2024 USD ($)	Feb. 29, 2024 USD ($) series	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
Commercial paper			$ 0		$ 0
Repayment of debt					300,000,000	$ 500,000,000
Proceeds from issuance of long-term debt					2,980,000,000	3,000,000,000
Interest and debt expense			131,000,000	$ 98,000,000	378,000,000	255,000,000
Interest costs capitalized			$ 5,000,000	$ 3,000,000	$ 16,000,000	$ 8,000,000
Notes due 2024 at 2.625%
Debt Instrument [Line Items]
Repayment of debt	$ 300,000,000
Long-term debt stated interest rate (in percentage)			2.625%		2.625%
Notes due 2027 at 4.60%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)			4.60%		4.60%
Notes due 2029 at 4.60%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)			4.60%		4.60%
Notes due 2034 at 4.85%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)			4.85%		4.85%
Notes due 2054 at 5.15%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)			5.15%		5.15%
Notes due 2063 at 5.05%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)			5.05%		5.05%
Senior unsecured notes
Debt Instrument [Line Items]
Number of series of debt issued \| series		5
Principal amount		$ 3,000,000,000
Debt issuance costs		16,000,000
Proceeds from issuance of long-term debt		2,980,000,000
Senior unsecured notes \| Notes due 2027 at 4.60%
Debt Instrument [Line Items]
Principal amount		$ 650,000,000
Long-term debt stated interest rate (in percentage)		4.60%
Senior unsecured notes \| Notes due 2029 at 4.60%
Debt Instrument [Line Items]
Principal amount		$ 650,000,000
Long-term debt stated interest rate (in percentage)		4.60%
Senior unsecured notes \| Notes due 2034 at 4.85%
Debt Instrument [Line Items]
Principal amount		$ 600,000,000
Long-term debt stated interest rate (in percentage)		4.85%
Senior unsecured notes \| Notes due 2054 at 5.15%
Debt Instrument [Line Items]
Principal amount		$ 750,000,000
Long-term debt stated interest rate (in percentage)		5.15%
Senior unsecured notes \| Notes due 2063 at 5.05%
Debt Instrument [Line Items]
Principal amount		$ 350,000,000
Long-term debt stated interest rate (in percentage)		5.05%
Revolving credit facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 1,000,000,000		$ 1,000,000,000

Debt and lines of credit - Sche

Debt and lines of credit - Schedule of Long-term Debt Outstanding (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total debt	$ 14,000	$ 11,300
Net unamortized discounts, premiums and issuance costs	(107)	(77)
Total debt, including net unamortized discounts, premiums and issuance costs	13,893	11,223
Current portion of long-term debt	(1,049)	(599)
Long-term debt	$ 12,844	10,624
Notes due 2024 at 2.625%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	2.625%
Total debt	$ 0	300
Notes due 2024 at 4.70%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.70%
Total debt	$ 300	300
Notes due 2025 at 1.375%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	1.375%
Total debt	$ 750	750
Notes due 2026 at 1.125%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	1.125%
Total debt	$ 500	500
Notes due 2027 at 4.60%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.60%
Total debt	$ 650	0
Notes due 2027 at 2.90%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	2.90%
Total debt	$ 500	500
Notes due 2028 at 4.60%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.60%
Total debt	$ 700	700
Notes due 2029 at 4.60%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.60%
Total debt	$ 650	0
Notes due 2029 at 2.25%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	2.25%
Total debt	$ 750	750
Notes due 2030 at 1.75%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	1.75%
Total debt	$ 750	750
Notes due 2031 at 1.90%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	1.90%
Total debt	$ 500	500
Notes due 2032 at 3.65%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	3.65%
Total debt	$ 400	400
Notes due 2033 at 4.90%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.90%
Total debt	$ 950	950
Notes due 2034 at 4.85%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.85%
Total debt	$ 600	0
Notes due 2039 at 3.875%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	3.875%
Total debt	$ 750	750
Notes due 2048 at 4.15%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.15%
Total debt	$ 1,500	1,500
Notes due 2051 at 2.70%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	2.70%
Total debt	$ 500	500
Notes due 2052 at 4.10%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	4.10%
Total debt	$ 300	300
Notes due 2053 at 5.00%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	5%
Total debt	$ 650	650
Notes due 2054 at 5.15%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	5.15%
Total debt	$ 750	0
Notes due 2063 at 5.05%
Debt Instrument [Line Items]
Long-term debt stated interest rate (in percentage)	5.05%
Total debt	$ 1,550	$ 1,200

Stockholders' equity (Details)

Stockholders' equity (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning			$ 16,897				$ 16,897
Net income	$ 1,362			$ 1,709			3,594	$ 5,139
Other comprehensive income (loss), net of taxes	5			$ 11			10	19
Balance, ending	$ 17,268						17,268
Cash dividends declared per common share (in dollars per share)	$ 1.30	$ 1.30	$ 1.30	$ 1.24	$ 1.24	$ 1.24
Cash dividends paid per common share (in dollars per share)	$ 1.30	$ 1.30	$ 1.30	$ 1.24	$ 1.24	$ 1.24
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning	$ 1,741	$ 1,741	$ 1,741	$ 1,741	$ 1,741	$ 1,741	1,741	1,741
Balance, ending	1,741	1,741	1,741	1,741	1,741	1,741	1,741	1,741
Paid-in Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning	3,666	3,439	3,362	3,163	3,016	2,951	3,362	2,951
Common stock issued for stock-based awards	62	111	(29)	38	36	(37)
Stock compensation	87	116	106	79	111	104
Other	(2)		0	0		(2)
Balance, ending	3,813	3,666	3,439	3,280	3,163	3,016	3,813	3,280
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning	52,135	52,199	52,283	51,522	50,930	50,353	52,283	50,353
Net income	1,362	1,127	1,105	1,709	1,722	1,708
Dividends declared and paid	(1,187)	(1,185)	(1,183)	(1,126)	(1,125)	(1,125)
Dividend equivalents on RSUs	(6)	(6)	(7)	(6)	(5)	(6)
Other	0		1	(1)		0
Balance, ending	52,304	52,135	52,199	52,098	51,522	50,930	52,304	52,098
Treasury Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning	(40,128)	(40,193)	(40,284)	(40,240)	(40,192)	(40,214)	(40,284)	(40,214)
Common stock issued for stock-based awards	55	137	94	35	29	118
Stock repurchases	(322)	(72)	(3)	(48)	(77)	(96)
Balance, ending	(40,395)	(40,128)	(40,193)	(40,253)	(40,240)	(40,192)	(40,395)	(40,253)
AOCI
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning	(200)	(203)	(205)	(246)	(252)	(254)	(205)	(254)
Other comprehensive income (loss), net of taxes	5	3	2	11	6	2
Balance, ending	$ (195)	$ (200)	$ (203)	$ (235)	$ (246)	$ (252)	$ (195)	$ (235)

Supplemental financial inform_3

Supplemental financial information - Restructuring Charges, Other (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disclosure Text Block Supplement [Abstract]
Restructuring charges/other	$ 0	$ 0	$ (124)	$ 0

Supplemental financial inform_4

Supplemental financial information -Other Current Assets (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Disclosure Text Block Supplement [Abstract]
U.S. CHIPS and Science Act investment tax credit	$ 621	$ 497
Other	341	264
Total	$ 962	$ 761

Supplemental financial inform_5

Supplemental financial information - Other Long-Term Assets (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Disclosure Text Block Supplement [Abstract]
U.S. CHIPS and Science Act investment tax credit	$ 806	$ 859
Operating lease right-of-use assets	800	579
Other	325	274
Total	$ 1,931	$ 1,712

Supplemental financial inform_6

Supplemental financial information - Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Disclosure Text Block Supplement [Abstract]
Operating lease liabilities	$ 681	$ 478
Other	671	858
Total	$ 1,352	$ 1,336

Supplemental financial inform_7

Supplemental financial information - Amounts Reclassified out of AOCI (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income (expense), net (OI&E)		$ 131	$ 128	$ 384	$ 327
Provision for income taxes		(192)	(213)	(500)	(731)
Net income		1,362	1,709	3,594	5,139
Reclassification out of Accumulated Other Comprehensive Income \| Net actuarial losses of defined benefit plans:
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income (expense), net (OI&E)	[1]	3	4	10	12
Provision for income taxes		(1)	(1)	(3)	(3)
Net income		2	3	7	9
Reclassification out of Accumulated Other Comprehensive Income \| Prior service cost (credit) of defined benefit plans:
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income (expense), net (OI&E)	[1]	1	1	1	1
Provision for income taxes		0	0	0	0
Net income		$ 1	$ 1	$ 1	$ 1

[1] Detailed in Note 5

Supplemental financial inform_8

Supplemental financial information - Treasury Stock (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance, beginning (in shares)			832
Balance, ending (in shares)	829
Treasury Common Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance, beginning (in shares)	828	831	832
Repurchases (in shares)	2	0	0
Shares issued for stock compensation (in shares)	(1)	(3)	(1)
Balance, ending (in shares)	829	828	831